APA (7th ed.) Citation

Pang, F., Dean, R., Jensen, I., Bean, K., Fields, C., & Miller, B. (2023). EE393 The Cost-Effectiveness of Atidarsagene Autotemcel (Arsa-Cel) for the Treatment of Metachromatic Leukodystrophy (MLD) in the US. Value in Health, 26(12), S126. https://doi.org/10.1016/j.jval.2023.09.659

Chicago Style (17th ed.) Citation

Pang, F., R. Dean, I.S Jensen, K. Bean, C. Fields, and B. Miller. "EE393 The Cost-Effectiveness of Atidarsagene Autotemcel (Arsa-Cel) for the Treatment of Metachromatic Leukodystrophy (MLD) in the US." Value in Health 26, no. 12 (2023): S126. https://doi.org/10.1016/j.jval.2023.09.659.

MLA (9th ed.) Citation

Pang, F., et al. "EE393 The Cost-Effectiveness of Atidarsagene Autotemcel (Arsa-Cel) for the Treatment of Metachromatic Leukodystrophy (MLD) in the US." Value in Health, vol. 26, no. 12, 2023, p. S126, https://doi.org/10.1016/j.jval.2023.09.659.